HNSBF (Hansa Biopharma AB) Cyclically Adjusted Revenue per Share: $0.12 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNSBF Hansa Biopharma AB HNSBF
43 GF Score
Price $3.70
GF Value $1.78
! 7 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Cyclically Adjusted Revenue per Share?

Hansa Biopharma AB HNSBF +27.59% 43 Cyclically Adjusted Revenue per Share is $0.12 as of Jun. 2026. GuruFocus rates HNSBF with a GF Score™ of 43/100 and a GF Value™ of $1.78. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hansa Biopharma AB's adjusted revenue per share for the three months ended in Jun. 2026 was $0.050. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.12 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Hansa Biopharma AB's average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 29.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hansa Biopharma AB was 74.20% per year. The lowest was 29.90% per year. And the median was 52.05% per year.

As of today (2026-07-31), Hansa Biopharma AB's current stock price is $3.70. Hansa Biopharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $0.12. Hansa Biopharma AB's Cyclically Adjusted PS Ratio of today is 30.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hansa Biopharma AB was 1122.33. The lowest was 18.06. And the median was 46.53.


Hansa Biopharma AB  (OTCPK:HNSBF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hansa Biopharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.70/0.12
=30.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hansa Biopharma AB was 1122.33. The lowest was 18.06. And the median was 46.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hansa Biopharma AB Cyclically Adjusted Revenue per Share Related Terms


Hansa Biopharma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Cyclically Adjusted Revenue per Share Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.06 0.07 0.08 0.12

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.10 0.12 0.13 0.12

HNSBF vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted PS Ratio falls into.


HNSBF
43GF Score
Hansa Biopharma AB HNSBF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.05/134.1100*134.1100
=0.050

Current CPI (Jun. 2026) = 134.1100.

Hansa Biopharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.003 101.138 0.004
201612 0.002 102.022 0.003
201703 0.003 102.022 0.004
201706 0.002 102.752 0.003
201709 0.002 103.279 0.003
201712 0.003 103.793 0.004
201803 0.002 103.962 0.003
201806 0.003 104.875 0.004
201809 0.001 105.679 0.001
201812 0.004 105.912 0.005
201903 0.002 105.886 0.003
201906 0.002 106.742 0.003
201909 0.002 107.214 0.003
201912 0.003 107.766 0.004
202003 0.002 106.563 0.003
202006 0.002 107.498 0.002
202009 0.002 107.635 0.002
202012 0.010 108.296 0.012
202103 0.024 108.360 0.030
202106 0.012 108.928 0.015
202109 0.013 110.338 0.016
202112 0.038 112.486 0.045
202203 0.071 114.825 0.083
202206 0.059 118.384 0.067
202209 0.138 122.296 0.151
202212 0.064 126.365 0.068
202303 0.044 127.042 0.046
202306 0.065 129.407 0.067
202309 0.039 130.224 0.040
202312 0.093 131.912 0.095
202403 0.102 132.205 0.103
202406 0.052 132.716 0.053
202409 0.070 132.304 0.071
202412 0.043 132.987 0.043
202503 0.097 132.825 0.098
202506 0.073 133.699 0.073
202509 0.039 133.480 0.039
202512 0.080 133.390 0.080
202603 0.036 133.560 0.036
202606 0.050 134.110 0.050

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.12 mean?
Hansa Biopharma AB (HNSBF) has a Cyclically Adjusted Revenue per Share of $0.12 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Cyclically Adjusted Revenue per Share too high?
Hansa Biopharma AB's current Cyclically Adjusted Revenue per Share is $0.12. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Hansa Biopharma AB's Cyclically Adjusted Revenue per Share of $0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Cyclically Adjusted Revenue per Share is $0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (HNSBF) has a current Cyclically Adjusted Revenue per Share of $0.12. The stock's GF Value™ is $1.78, compared to a current price of $3.70 — trading 107.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.12. Hansa Biopharma AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hansa Biopharma AB (HNSBF), the current Cyclically Adjusted Revenue per Share is $0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (HNSBF) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of $3.70 is trading 107.9% above its estimated GF Value™ of $1.78.

Key valuation signals for HNSBF:

  • Cyclically Adjusted Revenue per Share: $0.12
  • GF Value™: $1.78 vs. price of $3.70 (107.9% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the HNSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score

Get the complete analysis for HNSBF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.70
Price
$1.78
GF Value